| Literature DB >> 16295782 |
Jung-Mi Oh1, Seung-Hyun Kim, Chang-Hee Suh, Dong-Ho Nahm, Hae-Sim Park, Young-Mok Lee, June-Hyuk Lee, Choon-Sik Park, Hyung-Doo Shin.
Abstract
BACKGROUND: Glutathion S-transferase P1 (GSTP1), the abundant isoform of glutathione S-transferase in lung epithelium, plays an important role in cellular protection against oxidative stress and toxic foreign chemicals. GSTP1 (Ile105Val) polymorphism has been reported to be associated with asthma related phenotypes such as atopy and bronchial hyperresponsiveness. Therefore we investigated whether this polymorphism may be associated with the development of aspirin-intolerant asthma (AIA).Entities:
Mesh:
Substances:
Year: 2005 PMID: 16295782 PMCID: PMC3891158 DOI: 10.3904/kjim.2005.20.3.232
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Clinical characteristics of the subjects
†AIA, aspirin-intolerant asthma; NC, normal control; ATA, aspirin-tolerant asthma; N, number; NA, not applicable.
*Data is shown as mean value±S.D.
Clinical characteristics of the asthmatic subjects according to airway dysfunction
†PC20, Provocative dose of methacholine needed to reduce FEV1 by 20%.
‡Data is shown as mean value±S.D.
Allele and genotype frequencies of the GSTP1 Ile105Val polymorphism
†AIA, aspirin-intolerant asthma; NC, normal control; ATA, aspirin-tolerant asthma; N, number. *q.: rare allele frequency
‡Each p values waswere calculated with co-dominant, dominant, and recessive models. Logistic regression analysis was applied, controlling for age and sex as covariables.
Allele and genotype frequencies according to airway dysfunction
*q.: rare allele frequency. †Each p values was calculated with co-dominant, dominant, and recessive models. Logistic regression analysis was applied, controlling for age and sex as covariables.
Figure 1Association of the GSTP1 Ile105Val polymorphism with airway dysfunction. Subjects were divided into three groups according to their airway dysfunction: group I: FEV1 ≥ 80% predicted and PC20 ≥ 8 mg/mL; group II: FEV1 ≥ 80% predicted and PC20 < 8 mg/mL; group III: FEV1< 80% predicted.